© 2022 MJH Life Sciences and Ophthalmology Times. All rights reserved.

© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.

At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.

Cathleen McCabe, MD, recently discussed her presentation at the Women in Ophthalmology Summer Symposium, titled "GEMINI 1 and 2 pooled Phase 3 safety and efficacy: AGN-190584 primary and key secondary endpoints" 

McCabe discussed the trial, its results and the hope these drops could have for patients diagnosed with presbyopia.

Allergan, a subsidiary of AbbVie, announced last fall that the FDA had approved pilocarpine HCl Ophthalmic Solution 1.25% (Vuity) for the treatment of adult patients with presbyopia.

VIDEO: Eye trauma: Treatment trends and innovations

NYU Langone Health receives awards for quality, safety

Fulfilling expectations: A super highway to workability